Posted by Michael Wonder on 20 Jul 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions.
HLS Therapeutics welcomes the recent recommendation by the Canadian Agency for Drugs and Technologies in Health that Vascepa be reimbursed by participating public drug plans for statin-treated patients with established cardiovascular diseases and elevated triglycerides.
Having worked diligently to ensure an appropriate introductory price, HLS also received notification by the PMPRB that, further to its review, Vascepa's price did not trigger the investigation criteria for excessive pricing.
